Research Overview
· Last Reviewed May 2, 2026· PSI Editorial Board· IndependentCan Peptides Help Me Build Muscle?
The honest picture across 8 muscle-growth scenarios: what's been studied, what's confirmed in humans, and what nobody has shown yet.
WHAT ARE YOU INVESTIGATING?
Domain
Animal Studies
Human Trials
HIV-associated lipodystrophy
tesamorelin's FDA-approved indication
Adult growth hormone deficiency
diagnosed clinical condition
Sarcopenia
age-related muscle loss
Body composition (lean mass)
general adult population
Athletic muscle hypertrophy
performance enhancement
Post-injury muscle atrophy
recovery from disuse or trauma
Bodybuilding contests
competitive muscle gain
Pediatric GH deficiency
diagnosed clinical condition
How counts are scaled → · Tap any row to see the studies →
Quick Answer
Most peptides marketed for muscle growth work through the growth hormone axis. They reliably raise GH and IGF-1 markers. The translation to actual muscle hypertrophy is consistently modest in controlled trials. The largest effects on muscle in any human study still come from resistance training plus adequate protein.
Tesamorelin (sold as Egrifta) is the only FDA-approved compound on this page. The approval is narrow: HIV-associated lipodystrophy. Off-label use for general muscle growth is not supported by Phase 3 data in healthy adults. MK-677 is an oral GH secretagogue with the deepest controlled human body-composition data. Lean mass increases were roughly 1 to 1.5 kg in elderly populations (Nass et al. 2008). CJC-1295 and ipamorelin raise GH and IGF-1 in PK studies, with limited interventional muscle data. IGF-1 LR3 bypasses the pituitary and acts directly at muscle. It carries proliferative-risk concerns and lacks controlled human muscle trials.
The validated treatments for clinical conditions in this space are testosterone replacement (for hypogonadism) and recombinant human growth hormone (for diagnosed GH deficiency). Neither is a peptide on this page. For competitive athletes, every compound listed is prohibited under WADA Section S2. For current regulatory status, see the FDA Status Tracker. This page maps what's studied and what isn't, by muscle-growth scenario. For the parent body composition cluster including weight-loss therapies, see Peptides for Weight Loss.
Peptides vs testosterone replacement and recombinant growth hormone
Where research-grade peptides stand against the FDA-approved standards in this space
Most patients researching peptides for muscle growth have already heard of testosterone replacement therapy (TRT) and recombinant human growth hormone (somatropin). The honest comparison: TRT and somatropin are FDA-approved drugs with decades of large controlled trial evidence for diagnosed clinical conditions. Peptides for muscle growth are research-grade biology with much thinner clinical data, even tesamorelin (which is FDA-approved only for HIV-associated lipodystrophy, not for general muscle growth).
Testosterone replacement therapy is FDA-approved for diagnosed hypogonadism. Multiple large randomized controlled trials over 6 to 24 months have demonstrated lean body mass gains of 2 to 5 kg in hypogonadal men. Trials also documented fat mass losses, strength improvements, and quality-of-life changes. The TRAVERSE cardiovascular safety trial (Lincoff et al. 2023, PMID 37296572) provided the largest safety dataset to date. TRT is not appropriate for healthy young men with normal testosterone. It carries known risks including erythrocytosis, sleep apnea exacerbation, and prostate considerations. Effect sizes for muscle in hypogonadal patients are larger than effect sizes seen with any peptide on this page.
Recombinant human growth hormone (somatropin) is FDA-approved for pediatric and adult growth hormone deficiency, Turner syndrome, and several other indications. It is sold as Genotropin, Humatrope, Saizen, and Norditropin. In adult GH deficiency, somatropin produces lean body mass increases of 2 to 4 kg over 6 to 12 months. Trials also document fat mass decreases and quality-of-life improvements. Somatropin is the validated treatment for clinically diagnosed adult GHD. It is not approved for healthy adults seeking muscle growth or anti-aging. The most-cited Liu meta-analysis (Annals of Internal Medicine 2007, PMID 17204800) examined off-label use in healthy adults. The findings were minimal performance benefit and notable side effects.
Peptide evidence for muscle growth is much thinner than either of these standards. Tesamorelin has FDA approval but only for HIV lipodystrophy. MK-677 has the deepest body-composition data among GH secretagogues (about 1.1 kg lean mass over 12 months in elderly subjects). CJC-1295, ipamorelin, and IGF-1 LR3 have limited interventional human muscle data. None has matched the effect sizes documented for TRT in hypogonadism or somatropin in GHD.
PSI's reading: for diagnosed clinical hypogonadism or growth hormone deficiency, the FDA-approved standards (TRT and somatropin) have far stronger evidence than peptides on this page. For healthy adults seeking muscle growth, the largest documented effects in any controlled trial come from resistance training with adequate protein intake. Peptides may produce small additional effects on lean mass in some populations. They do not produce the muscle gains marketing materials suggest. Anyone framing peptides as primary muscle-growth therapy in 2026 is reading further into the data than the data supports.
GH secretagogues vs direct IGF-1 (CJC-1295/ipamorelin vs IGF-1 LR3)
Indirect pituitary stimulation vs direct tissue-level action
GH secretagogues (CJC-1295, ipamorelin, MK-677, sermorelin, tesamorelin, GHRPs) work indirectly. They tell the pituitary to release more GH, which then circulates and triggers IGF-1 production primarily in the liver. The advantage of this approach is that the body's normal feedback mechanisms remain intact. If GH levels rise too far, somatostatin signaling can dampen pituitary output, and IGF-1 binding proteins regulate tissue-level activity.
IGF-1 LR3 works directly. It bypasses the hypothalamus and pituitary, acting at IGF-1 receptors on muscle and other tissues. The Long-R3 modification reduces binding to IGF-binding proteins, which extends the functional half-life and increases tissue-level activity. The mechanistic argument for IGF-1 LR3 is that it produces stronger anabolic signaling at the target tissue without the regulatory dampening that limits secretagogue effects.
The clinical-evidence picture is the opposite of what the mechanism rationale would suggest. GH secretagogues have more controlled human trial data than IGF-1 LR3. MK-677 has 12-month elderly RCT data with documented body composition effects. Tesamorelin has FDA-approved Phase 3 trial data in HIV lipodystrophy. CJC-1295 has Phase 1 and 2 PK data in healthy adults. IGF-1 LR3 has zero published controlled human trials for muscle hypertrophy. The compound exists in the research-chemical market without any controlled clinical evaluation.
Safety profiles also differ. GH secretagogues operate within the body's natural feedback system. They can elevate fasting glucose and produce mild edema, but they do not carry the direct proliferative-risk concerns that IGF-1 LR3 does. IGF-1 receptor activation is implicated in cancer cell biology, and elevated systemic IGF-1 has been associated with increased cancer incidence in some observational studies. IGF-1 LR3 is one of the higher-risk peptides in this category.
PSI's reading: for someone exploring muscle-growth peptides under physician supervision, GH secretagogues with documented PK data are a more defensible category than direct IGF-1 analogs. The defensible secretagogues include CJC-1295, ipamorelin, and tesamorelin. Even within secretagogues, the only FDA-approved option is tesamorelin, and the only approved indication is HIV lipodystrophy. Off-label use for muscle growth is research-grade exploration in all cases. Direct IGF-1 LR3 use carries the steepest evidence-to-claim mismatch and the most concerning safety profile of compounds discussed for muscle growth in 2026.
Peptides vs resistance training and protein for muscle growth
The intervention with the strongest evidence is the one without a needle
The largest documented effects on muscle in any controlled human trial come from resistance training plus adequate protein intake. Not from any peptide. This is a load-bearing fact for any honest discussion of muscle-growth peptides.
Meta-analyses of resistance training in untrained adults consistently show 1 to 2 kg of lean body mass gain over 8 to 12 weeks of progressive resistance training. Much larger gains follow over 6 to 24 months in adherent subjects. Morton et al. (British Journal of Sports Medicine 2018, PMID 28698222) meta-analyzed 49 studies with 1,863 participants. The Morton analysis demonstrated that protein supplementation enhanced resistance-training-induced gains in fat-free mass. Effect sizes scale with training experience, training intensity, and protein intake.
These training effect sizes are similar to or larger than the effect sizes documented for MK-677 in elderly populations (about 1.1 kg over 12 months). Untrained adults gain 1 to 2 kg per 12 weeks. Experienced lifters can gain multiple kilograms over years. Resistance training produces functional strength, structural adaptation, and durable changes. Those adaptations survive cessation of stimulus better than peptide-induced effects, which typically reverse within months of stopping.
The peptide-marketing framing suggests peptides are an additive enhancement on top of training. The trial evidence for that framing is sparse. There are no adequately powered controlled trials of CJC-1295, ipamorelin, or IGF-1 LR3 in trained athletes performing structured resistance training. None of those trials evaluated muscle hypertrophy as a primary endpoint. The closest analog is the somatropin literature in healthy adult athletes. That literature is largely negative for performance benefit (Liu meta-analysis, Annals of Internal Medicine 2007, PMID 17204800).
PSI's reading: for healthy adults seeking muscle growth, the dominant intervention with the strongest evidence is resistance training with adequate protein intake. Peptides may add small effects in specific populations (elderly subjects, hypogonadal men, HIV lipodystrophy patients) or specific clinical conditions. Healthy young adults pursuing muscle hypertrophy through peptides are pursuing a research-grade intervention with modest-at-best documented effect sizes when training is the comparator. The peptide is not doing the bulk of the work in any of these scenarios.
The Compounds, Ranked by Evidence
Ordered by strength of controlled human data, not popularity.
Across the 5 most-discussed peptides for muscle growth, PSI catalogs the published animal studies and human trials below. None of these compounds has FDA approval for muscle growth.
Tesamorelin
Only FDA-approved compound on this page. Approval is narrow: HIV-associated lipodystrophy. Phase 3 trial data exists in that population. Off-label muscle-growth use lacks Phase 3 evidence.
WADA Section S2 prohibition. Tesamorelin is prohibited under the World Anti-Doping Agency code. Athletes subject to drug testing should not use this compound.
Counts are PubMed-indexed papers and registered clinical trials. Scale: Strong 10+, Moderate 4–9, Limited 1–3, None 0. Methodology →
| Injury Area | Animal Studies | Human Trials |
|---|---|---|
HIV-associated lipodystrophy FDA-approved indication | 8 Reduced visceral adipose tissue and improved metabolic markers reported in animal models. | 4 Phase 3 RCTs in HIV-associated lipodystrophy demonstrated reduced VAT, increased IGF-1, and modest lean body mass changes. FDA approved November 2010. |
Adult GH deficiency off-label diagnostic use | 3 Improved IGF-1 markers reported in animal GHD models. | 1 Off-label use in adult GHD is reported in clinical practice. Controlled trial evidence is limited compared to recombinant somatropin. |
Body composition in healthy adults off-label muscle/lean mass use | 2 Limited animal data for healthy non-disease populations. | 0 No published Phase 3 RCTs in healthy adults. Body composition extension is off-label and lacks adequately powered evidence. |
Sarcopenia age-related muscle loss | 2 Limited animal data specific to age-related muscle loss. | 0 No published interventional trials of tesamorelin specifically for sarcopenia in elderly populations. |
MK-677
Deepest controlled human body-composition data. 12-month elderly RCT showed about 1.1 kg lean mass increase. Not technically a peptide. WADA-prohibited.
WADA Section S2 prohibition. MK-677 is prohibited under the World Anti-Doping Agency code. Athletes subject to drug testing should not use this compound.
| Injury Area | Animal Studies | Human Trials |
|---|---|---|
Body composition in elderly lean mass, fat mass | 5 Increased lean body mass and decreased fat mass reported in aged rodent models. | 2 12-month RCT in 65 healthy older adults reported lean body mass increase of approximately 1.1 kg. Effects partly reflect water retention. |
Bone density (elderly) BMD changes | 3 Improved bone formation markers reported in aged rodent models. | 1 Bone mineral density improvement reported in the 12-month elderly RCT. |
Sarcopenia age-related muscle loss | 4 Reversal of age-associated muscle decline reported in aged rodent models. | 1 The 12-month elderly trial supports modest sarcopenia-relevant effects, but MK-677 is not FDA-approved for sarcopenia. |
Athletic muscle hypertrophy trained adults | 2 Limited animal data for trained or athletic populations. | 0 No published RCTs in trained athletes. Effect sizes in healthy adult populations are typically modest. |
Catabolic conditions wasting, post-surgical | 3 Reduced catabolic muscle loss reported in animal models. | 1 Small trials in catabolic conditions have explored MK-677 but did not produce FDA approval pathways. |
CJC-1295
Phase 1 and 2 PK studies confirm sustained IGF-1 elevation up to 28 days. No controlled muscle-hypertrophy trials.
WADA Section S2 prohibition. CJC-1295 is prohibited under the World Anti-Doping Agency code. Athletes subject to drug testing should not use this compound.
| Injury Area | Animal Studies | Human Trials |
|---|---|---|
GH and IGF-1 elevation pharmacokinetic studies | 4 Sustained GH and IGF-1 elevation reported in animal PK studies. | 2 Phase 1 and 2 studies confirmed sustained IGF-1 elevation in healthy adults. Trials were short-duration without muscle hypertrophy endpoints. |
Body composition lean mass, fat mass | 2 Limited animal data for body composition specifically. | 0 No published controlled trials with body composition as a primary endpoint. |
Adult GH deficiency off-label diagnostic use | 1 Limited animal data for diagnosed GHD. | 0 No published controlled GHD trials. Off-label clinical use exists but lacks Phase 3 evidence. |
Athletic muscle hypertrophy trained adults | 1 Limited animal hypertrophy data. | 0 No published RCTs. WADA-prohibited in competitive sport. |
Ipamorelin
Phase 1 PK data confirms selective GH release without cortisol or prolactin spikes. No controlled muscle-hypertrophy trials.
WADA Section S2 prohibition. Ipamorelin is prohibited under the World Anti-Doping Agency code. Athletes subject to drug testing should not use this compound.
| Injury Area | Animal Studies | Human Trials |
|---|---|---|
GH release (acute and sustained) pharmacokinetic studies | 5 Consistent acute GH elevation reported in animal PK studies. | 2 Phase 1 studies confirmed selective GH release in healthy adults without cortisol or prolactin spikes. |
Body composition lean mass, fat mass | 2 Limited animal data for body composition outcomes. | 0 No published controlled trials with body composition as a primary endpoint. |
Athletic muscle hypertrophy trained adults | 1 Limited animal hypertrophy data. | 0 No published RCTs. WADA-prohibited in competitive sport. |
Post-surgical recovery ileus, catabolic states | 3 Improved post-surgical recovery markers reported in animal models. | 1 Small post-operative ileus trial discontinued. No FDA approval pathway. |
IGF-1 LR3
Direct IGF-1 receptor activation. Zero published controlled human muscle trials. Carries proliferative-risk concerns. Steepest evidence-to-claim mismatch on this page.
WADA Section S2 prohibition. IGF-1 LR3 is prohibited under the World Anti-Doping Agency code. Athletes subject to drug testing should not use this compound.
| Injury Area | Animal Studies | Human Trials |
|---|---|---|
Muscle protein synthesis in vitro and animal | 6 Direct stimulation of muscle protein synthesis reported in animal models and cell culture. | 0 No published controlled human trials of IGF-1 LR3 for muscle hypertrophy. |
Body composition healthy adults | 3 Increased lean mass reported in animal models. | 0 No published RCTs in healthy human adults. |
Catabolic conditions wasting, sarcopenia | 4 Reversal of catabolic muscle loss reported in animal models. | 0 No published RCTs in catabolic patient populations. |
Cancer/proliferation risk safety signal | 5 IGF-1 receptor activation implicated in cancer cell biology in multiple animal and cell-culture models. | 0 Elevated systemic IGF-1 associated with increased cancer incidence in some observational studies. No interventional safety data for IGF-1 LR3 specifically. |
What's Marketed vs What's Studied
6 common claims, corrected.
“Higher GH levels automatically mean more muscle.”
GH and IGF-1 elevation are pharmacokinetic markers. The translation to actual muscle hypertrophy is modest and depends on baseline status, training, and nutrition. Most studies in healthy adults show small lean mass effects.
“CJC-1295 and ipamorelin together produce dramatic muscle gains.”
The stack is mechanistically reasonable. No controlled human trial has tested the combination for muscle hypertrophy. The PK studies that exist confirm IGF-1 elevation but do not document hypertrophy outcomes.
“IGF-1 LR3 is safer than steroids because it is a peptide.”
IGF-1 LR3 carries direct proliferative-risk concerns through IGF-1 receptor activation. Long-term safety data does not exist. Calling it safer than other anabolic compounds is not supported by evidence.
“Tesamorelin works for general muscle growth in healthy adults.”
Tesamorelin's FDA approval is for HIV-associated lipodystrophy. Phase 3 data exists in that population. There are no Phase 3 trials in healthy adults for general muscle growth.
“Peptides are equivalent alternatives to TRT or growth hormone replacement.”
TRT for hypogonadism and somatropin for diagnosed GHD have decades of trial evidence with effect sizes larger than any peptide on this page. Peptides are research-grade alternatives at best, not equivalents.
“MK-677 is a muscle-building peptide.”
MK-677 is technically not a peptide. It is a small-molecule ghrelin receptor agonist. The lean body mass effects in trials are modest (about 1.1 kg) and partly reflect water retention. It is included in this category because every muscle-growth peptide conversation routes through it.
If Considering Use, Here Is How to Be Safe
How to evaluate sources, verify quality, and find qualified physicians.
Establish a structured training and nutrition base first.
Resistance training with progressive overload produces larger documented muscle effects than any peptide on this page. Key elements: training volume of 10 to 20 sets per muscle group per week, and protein intake of 1.6 to 2.2 g/kg body weight daily. Optimize these before considering peptides as adjuncts.
Work with a licensed physician who knows both validated standards and peptide research.
Avoid clinics whose primary business is selling peptides. A qualified physician can evaluate diagnosis and screen for underlying conditions like hypogonadism or GHD. Look for endocrinology, sports medicine, or anti-aging specialists with peptide experience. The right physician frames peptides accurately as research-grade adjuncts rather than primary therapy.
Tesamorelin is FDA-approved only for HIV lipodystrophy.
Off-label prescribing for general muscle growth or body composition exists but lacks Phase 3 evidence. Insurance does not cover off-label use. Direct-pay pricing for Egrifta is substantial.
Compounded peptides require physician prescription and licensed pharmacy.
503A pharmacies prepare patient-specific compounds; 503B outsourcing facilities prepare office-use stock. Both require active state pharmacy board licensure. Demand third-party HPLC purity testing and certificates of analysis on each batch.
WADA-prohibited compounds carry career risk for athletes.
Every compound on this page is prohibited under WADA Section S2 in competitive sport. Out-of-competition testing applies year-round. Athletes subject to WADA jurisdiction should treat this as disqualifying for competitive use, regardless of off-season timing.
Watching and waiting plus optimizing training is a legitimate option.
Stronger human evidence may come from ongoing peptide research over years. Training and nutrition produce documented effects today. There is no penalty for being patient with peptide adoption while optimizing the validated interventions.
The regulatory landscape for muscle-growth peptides is dynamic. Tesamorelin (Egrifta) is FDA-approved with continued post-marketing safety monitoring; the approval remains narrow for HIV lipodystrophy. MK-677 development was discontinued by Merck without FDA approval; the compound persists as a research chemical. CJC-1295, ipamorelin, GHRP-2, GHRP-6, hexarelin, and IGF-1 LR3 have no FDA approval pathways currently in progress. The Outsourcing Facilities Association is actively litigating FDA compounding decisions in the Northern District of Texas, which could shift availability of multiple compounded peptides. WADA's Section S2 prohibition applies to all compounds on this page; detection methods for GH-releasing peptides continue to evolve. PSI tracks these developments and updates this page as material changes occur.
Find a verified physician
PSI's directory only lists physicians who have passed a five-gate verification process: state board active, no disciplinary actions, peptide-category competency, transparent pricing, and patient outcome documentation.
Browse the directoryLearn about the verification process →Common Questions
Do peptides actually build muscle?
Most peptides marketed for muscle growth reliably elevate GH and IGF-1 in pharmacokinetic studies. The translation to actual muscle hypertrophy in controlled human trials is consistently modest. MK-677 produces about 1.1 kg lean mass increase over 12 months in elderly populations. Tesamorelin produces similar modest effects in HIV lipodystrophy. CJC-1295, ipamorelin, and IGF-1 LR3 lack controlled human muscle-hypertrophy trials. The largest documented effects on muscle in any controlled trial come from resistance training plus adequate protein intake. Those effects do not come from any peptide on this page. Anyone framing peptides as primary muscle-growth therapy is overstating the evidence.
Is tesamorelin FDA-approved for muscle growth?
No. Tesamorelin (sold as Egrifta) received FDA approval in November 2010 for one narrow indication: reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The Phase 3 trial published in NEJM 2007 (Falutz et al., PMID 17671248) supported approval in that population. Off-label use for muscle growth in healthy adults is not supported by Phase 3 data. The mechanism is GHRH receptor agonism producing sustained IGF-1 elevation. That mechanism is plausibly relevant to muscle growth. No Phase 3 RCT in healthy adults has tested tesamorelin for that indication. Tesamorelin is WADA-prohibited under Section S2 in competitive athletes.
What are the actual results from MK-677 trials?
The Nass 2008 trial (Annals of Internal Medicine, PMID 19000932) is the deepest controlled human body-composition study of MK-677. It randomized 65 healthy older adults to 25mg daily MK-677 or placebo for one year. The MK-677 arm showed sustained GH and IGF-1 elevation, lean body mass increase of about 1.1 kg, and bone mineral density improvement. The lean mass increase partly reflects water retention from GH-induced fluid effects. Adverse effects included sustained appetite increase, mild peripheral edema, and modest fasting glucose elevation. MK-677 is not FDA-approved for any indication. Development was discontinued in part due to glucose tolerance concerns. The compound is widely available as a research chemical.
Should I stack CJC-1295 with ipamorelin?
The stacking rationale is mechanistic. CJC-1295 is a GHRH analog that produces sustained GH and IGF-1 elevation through pituitary GHRH receptors. Ipamorelin is a selective GHRP that produces pulsatile GH release through ghrelin receptors. The two pathways are non-overlapping at the receptor level. Combining them theoretically produces both sustained and pulsatile GH elevation. The clinical evidence for the combination in muscle hypertrophy is absent. No published controlled human trial has tested CJC-1295 with ipamorelin for any clinical endpoint, including muscle growth. PK studies of each compound separately confirm the proposed mechanisms. The decision to use a stacked combination should be discussed with a physician familiar with the peptide research.
Is IGF-1 LR3 safe to use for muscle growth?
IGF-1 LR3 carries the most concerning safety profile of compounds discussed for muscle growth in 2026. The direct mechanism (IGF-1 receptor activation at tissue level) is implicated in cancer cell biology. Elevated systemic IGF-1 has been associated with increased cancer incidence in observational studies, particularly for prostate, breast, and colorectal cancers. There are no adequately powered controlled human trials of IGF-1 LR3 for muscle hypertrophy. There are no long-term safety trials. The compound is research-only with no FDA approval. WADA prohibits IGF-1 LR3 under Section S2. PSI's reading: IGF-1 LR3 carries the steepest evidence-to-claim mismatch on this page. The mechanism rationale is straightforward. The clinical evidence and long-term safety data are essentially absent.
How do peptides compare to testosterone replacement therapy for muscle?
Testosterone replacement therapy (TRT) is FDA-approved for diagnosed hypogonadism. Multiple large randomized controlled trials over 6 to 24 months have demonstrated lean body mass gains of 2 to 5 kg in hypogonadal men. The TRAVERSE cardiovascular safety trial (Lincoff et al. 2023, PMID 37296572) provided the largest safety dataset to date. Effect sizes for muscle in hypogonadal patients are larger than effect sizes seen with any peptide on this page. Peptides are not equivalent alternatives to TRT for hypogonadism. They are research-grade biology with much thinner clinical data. For healthy young men with normal testosterone, neither TRT nor peptides are appropriate primary interventions for muscle growth. Resistance training with adequate protein intake is the validated approach.
How do peptides compare to recombinant growth hormone (somatropin)?
Recombinant human growth hormone (somatropin) is FDA-approved for pediatric and adult growth hormone deficiency, Turner syndrome, and several other indications. It is sold as Genotropin, Humatrope, Saizen, and Norditropin. In adult GHD, somatropin produces lean body mass increases of 2 to 4 kg and fat mass decreases over 6 to 12 months. Effect sizes are larger than any peptide on this page. The Liu et al. meta-analysis (Annals of Internal Medicine 2007, PMID 17204800) examined off-label somatropin use in healthy adults. The findings were minimal performance benefit with notable side effects. The peptides on this page (tesamorelin, MK-677, CJC-1295, ipamorelin) work indirectly by increasing the body's own GH production. They have not produced effect sizes comparable to recombinant somatropin in head-to-head data. For diagnosed GHD, somatropin is the validated treatment. Peptides are research-grade alternatives at best.
Are these peptides legal?
Regulatory status varies by compound and jurisdiction. Tesamorelin (Egrifta) is FDA-approved and legally prescribed for HIV-associated lipodystrophy. MK-677 has no FDA approval and is widely available as a research chemical. CJC-1295, ipamorelin, GHRP-2, GHRP-6, hexarelin, and IGF-1 LR3 are research compounds without FDA approval for any indication. Compounded peptide formulations for human use require a physician prescription and a state-licensed compounding pharmacy. WADA prohibits all GH secretagogues, GHRH analogs, GHRPs, and IGF-1 analogs under Section S2 in competitive athletes. Out-of-competition testing applies year-round for athletes subject to WADA jurisdiction. Regulatory status is dynamic and varies by country.
What are the side effects of GH secretagogues?
Common GH secretagogue effects include peripheral edema (swelling, particularly in hands and feet) and arthralgia (joint pain). Other common effects include insulin resistance, elevated fasting glucose, mild fatigue, and increased appetite. MK-677 specifically produces sustained appetite elevation due to ghrelin receptor activation. CJC-1295 and tesamorelin can produce injection-site reactions. Ipamorelin is generally well-tolerated and selective, with fewer cortisol or prolactin effects than older GHRPs. Long-term effects of chronic GH and IGF-1 elevation include theoretical concerns about cancer risk, cardiovascular changes, and acromegalic-like features at high doses. Long-term controlled safety data is incomplete for most compounds. Glucose tolerance should be monitored in anyone using GH secretagogues for extended periods.
How long does it take peptides to produce muscle growth effects?
Pharmacokinetic markers (GH and IGF-1 elevation) appear within hours to days of beginning peptide use. Body composition changes appear on a much longer timeline. The Nass 2008 MK-677 trial documented lean mass increase over 12 months. The Falutz 2007 tesamorelin Phase 3 trial measured outcomes at 26 weeks. CJC-1295 and ipamorelin lack controlled trials with muscle endpoints. Anyone evaluating peptides for muscle growth should expect a minimum 3 to 6 month timeline before any meaningful body-composition assessment. Photograph at baseline. Measure body composition with a consistent method (DEXA preferred, otherwise calipers or BIA at the same time of day). Track strength benchmarks. Expect modest effects, not dramatic ones.
Can I combine peptides with resistance training?
The intersection of peptides and resistance training has not been studied in adequately powered controlled trials with muscle hypertrophy as a primary endpoint. The mechanism rationale for combining them is reasonable. Peptides could theoretically enhance training-induced anabolic signaling. The evidence-based reality is that resistance training plus adequate protein intake produces the largest documented effects on muscle in any controlled human study, with or without peptide adjuncts. Anyone considering peptide use should establish a structured resistance training program first. Key training elements include progressive overload, sufficient training volume, and protein intake of 1.6 to 2.2 g/kg body weight daily. The peptide is not doing the bulk of the work in any scenario where training is suboptimal. Combining peptides with high-quality training is more defensible than relying on peptides without training.
Are peptides for muscle growth banned in sports?
Yes. Every compound on this page is prohibited under WADA Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). This includes tesamorelin, MK-677, CJC-1295 (with or without DAC), ipamorelin, sermorelin, GHRP-2, GHRP-6, hexarelin, and IGF-1 LR3. Out-of-competition testing applies year-round for athletes subject to WADA jurisdiction. The prohibition applies to NCAA athletes, Olympic-level athletes, and most professional sports leagues that adopt WADA standards. Detection methods for GH-releasing peptides have improved substantially. Athletes considering these compounds should understand that the testing landscape continues to evolve. The consequences of an adverse analytical finding include sanctions and career-ending bans.
Is sermorelin a good alternative to CJC-1295?
Sermorelin is an older GHRH analog with a much shorter half-life than CJC-1295 with DAC. Sermorelin's half-life is about 12 minutes. CJC-1295 with DAC's half-life is about 6 to 8 days due to albumin binding. Sermorelin produces more pulsatile GH elevation that mimics natural physiology more closely. CJC-1295 with DAC produces more sustained elevation. Sermorelin has historical FDA approval for pediatric GH deficiency (under the brand name Geref), but it was discontinued in the United States. Ongoing clinical use of sermorelin in adult GHD or off-label muscle-growth contexts relies on compounded formulations. Both compounds raise GH and IGF-1 in PK studies. Neither has controlled human muscle-hypertrophy trials. Sermorelin is generally considered to have a more reassuring safety profile due to its shorter half-life and physiological pulsatile pattern. Evidence-based comparison to CJC-1295 is limited.
What about BPC-157 and TB-500 for muscle recovery?
[BPC-157](/peptide-library/bpc-157) and [TB-500](/peptide-library/tb-500) are tissue-repair peptides covered in detail on the [injury recovery condition page](/conditions/peptides-for-injury-recovery). They do not directly stimulate muscle hypertrophy. Their proposed value for muscle is indirect, through faster recovery from training-induced damage or injury, which could theoretically allow more frequent or higher-volume training. The evidence base for both compounds is overwhelmingly preclinical. Three small uncontrolled human BPC-157 studies, all from one Florida clinical group, total fewer than 30 patients. None concerned muscle hypertrophy. TB-500 has zero published controlled human injury trials. WADA prohibits both compounds under Section S2. PSI's reading: framing BPC-157 or TB-500 as muscle-growth peptides overstates their evidence base. They are tissue-repair peptides with theoretical recovery applications, not anabolic compounds.
What questions should I ask a doctor about peptides for muscle growth?
Ask: (1) Do I have a diagnosed clinical condition (hypogonadism, growth hormone deficiency, sarcopenia) where evidence-based treatment exists? Treatment depends on diagnosis. (2) Have I optimized resistance training, protein intake, sleep, and recovery before considering peptides? Those produce the largest documented muscle effects in any controlled trial. (3) What evidence level supports the peptide being considered, and is it animal data, PK data, or interventional human muscle data? (4) Is the peptide WADA-prohibited, and does that affect me as an athlete or in my profession? (5) What are the long-term safety considerations, particularly for IGF-1 receptor activation and cancer risk? (6) Are the formulations being prescribed from a state-licensed compounding pharmacy with third-party analytical testing?
Will peptides help me build muscle if my testosterone is normal?
For healthy young men with normal testosterone, the evidence base for peptide-driven muscle growth is thin. The compounds with the strongest data (MK-677, tesamorelin) were studied in elderly populations or in HIV lipodystrophy patients, not in healthy young adults. Effect sizes in those clinical populations were modest (1 to 2 kg lean mass over months). Effect sizes in healthy young adults with normal hormone profiles have not been adequately studied in controlled trials. The dominant intervention for muscle growth in this population, by trial evidence, is resistance training with adequate protein intake. Anyone with normal testosterone considering peptides for muscle growth is pursuing a research-grade intervention with limited evidence specific to their population. The honest framing: peptides may add small effects on top of training. They will not produce the dramatic gains that anabolic steroids produce. The trial evidence supporting even modest gains in healthy young adults is thin.
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.